Sugi Predict

Sugi Predict / Compounds / SCHEMBL1365989

SCHEMBL1365989

SCHEMBL1365989

Cc1c(Br)cnc2c1N(Cc1c(F)ccc(F)c1Cl)CCN2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 6/20 0.50
▸ JAK2 O60674 2/20 0.50
▸ PRKD3 O94806 2/20 0.50
▸ MAP4K4 O95819 2/20 0.50
▸ ABL1 P00519 2/20 0.50
▸ LCK P06239 2/20 0.50
▸ CSF1R P07333 2/20 0.50
▸ RET P07949 2/20 0.50
▸ MET P08581 2/20 0.50
▸ FGFR1 P11362 2/20 0.50
▸ LTK P29376 2/20 0.50
▸ FLT3 P36888 2/20 0.50
▸ PTK2 Q05397 2/20 0.50
▸ MAP4K2 Q12851 2/20 0.50
▸ NTRK2 Q16620 2/20 0.50
▸ TAOK1 Q7L7X3 2/20 0.50
▸ AURKB Q96GD4 2/20 0.50
▸ MAP4K5 Q9Y4K4 2/20 0.50
▸ PLK4 O00444 1/20 0.50
▸ ROS1 P08922 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12146408 0.78 ALK (0.61) ALKJAK2PRKD3MAP4K4ABL1
SCHEMBL19908211 0.78 ALK (0.64) ALKJAK2PRKD3MAP4K4ABL1
SCHEMBL1365924 0.78 ALK (0.49) ALKJAK2PRKD3MAP4K4ABL1
SCHEMBL12146366 0.76 ALK (0.49) ALKJAK2PRKD3MAP4K4ABL1
SCHEMBL12146452 0.76 MET (0.41) ALKJAK2PRKD3MAP4K4ABL1
SCHEMBL12146467 0.76 ALK (0.51) ALKJAK2PRKD3MAP4K4ABL1
SCHEMBL12146447 0.76 ALK (0.48) ALKJAK2PRKD3MAP4K4ABL1
SCHEMBL12146409 0.76 PLK4 (0.46) ALKJAK2PRKD3MAP4K4ABL1
SCHEMBL1368537 0.76 MAP4K3 (0.46) ALKJAK2PRKD3MAP4K4ABL1
SCHEMBL12147231 0.76 PLK4 (0.43) ALKJAK2PRKD3MAP4K4ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2365809-B1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMA INC (US) 2018-07-18 — — EP disclosed
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. 2014-12-11 — — US disclosed
US-8846664-B2 Pyrazinopyrazines and derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-09-30 — — US disclosed
US-20110288078-A1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2011-11-24 — — US disclosed
EP-2365809-A1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS ARIAD Pharmaceuticals, Inc (US) 2011-09-21 — — EP disclosed
WO-2010056311-A1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2010-05-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors MAP3K5, MAP3K15, MAP4K2 ALK 286/4885JAK2 151/4885PRKD3 130/4885
US-20110288078-A1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS MAP3K5, MAP3K15, MAP4K2 ALK 286/4885JAK2 151/4885PRKD3 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.